Literature DB >> 26863087

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5.

Eric Ehrke-Schulz1, Wenli Zhang1, Maren Schiwon1, Thorsten Bergmann1, Manish Solanki1, Jing Liu1, Philip Boehme1, Theo Leitner1, Anja Ehrhardt2.   

Abstract

High-capacity adenoviral vectors (HCAdV) devoid of all viral coding sequences represent one of the most advanced gene delivery vectors due to their high packaging capacity (up to 35 kb), low immunogenicity and low toxicity. However, for many laboratories the use of HCAdV is hampered by the complicated procedure for vector genome construction and virus production. Here, a detailed protocol for efficient cloning and production of HCAdV based on the plasmid pAdFTC containing the HCAdV genome is described. The construction of HCAdV genomes is based on a cloning vector system utilizing homing endonucleases (I-CeuI and PI-SceI). Any gene of interest of up to 14 kb can be subcloned into the shuttle vector pHM5, which contains a multiple cloning site flanked by I-CeuI and PI-SceI. After I-CeuI and PI-SceI-mediated release of the transgene from the shuttle vector the transgene can be inserted into the HCAdV cloning vector pAdFTC. Because of the large size of the pAdFTC plasmid and the long recognition sites of the used enzymes associated with strong DNA binding, careful handling of the cloning fragments is needed. For virus production, the HCAdV genome is released by NotI digest and transfected into a HEK293 based producer cell line stably expressing Cre recombinase. To provide all adenoviral genes for adenovirus amplification, co-infection with a helper virus containing a packing signal flanked by loxP sites is required. Pre-amplification of the vector is performed in producer cells grown on surfaces and large-scale amplification of the vector is conducted in spinner flasks with producer cells grown in suspension. For virus purification, two ultracentrifugation steps based on cesium chloride gradients are performed followed by dialysis. Here tips, tricks and shortcuts developed over the past years working with this HCAdV vector system are presented.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26863087      PMCID: PMC4781703          DOI: 10.3791/52894

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  12 in total

1.  A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.

Authors:  H Mizuguchi; M A Kay
Journal:  Hum Gene Ther       Date:  1999-08-10       Impact factor: 5.695

Review 2.  Adenovirus vectors for gene delivery.

Authors:  K Benihoud; P Yeh; M Perricaudet
Journal:  Curr Opin Biotechnol       Date:  1999-10       Impact factor: 9.740

3.  Improved system for helper-dependent adenoviral vector production.

Authors:  Donna Palmer; Philip Ng
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

4.  A rapid protocol for construction and production of high-capacity adenoviral vectors.

Authors:  Lorenz Jager; Martin A Hausl; Christina Rauschhuber; Nicola M Wolf; Mark A Kay; Anja Ehrhardt
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 5.  Helper dependent adenovirus vectors: progress and future prospects.

Authors:  Dan Cots; Assumpció Bosch; Miguel Chillón
Journal:  Curr Gene Ther       Date:  2013-10       Impact factor: 4.391

6.  High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity.

Authors:  N Morral; R J Parks; H Zhou; C Langston; G Schiedner; J Quinones; F L Graham; S Kochanek; A L Beaudet
Journal:  Hum Gene Ther       Date:  1998-12-10       Impact factor: 5.695

7.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo.

Authors:  Anja Ehrhardt; Mark A Kay
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

9.  Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.

Authors:  Daniel A Muruve; Matthew J Cotter; Anne K Zaiss; Lindsay R White; Qiang Liu; Trevor Chan; Sharon A Clark; P Joel Ross; Robert A Meulenbroek; Gunhild M Maelandsmo; Robin J Parks
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.

Authors:  Anja Ehrhardt; Hui Xu; Aaron M Dillow; Dwight A Bellinger; Timothy C Nichols; Mark A Kay
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  6 in total

1.  Cellular Zinc Finger Protein 622 Hinders Human Adenovirus Lytic Growth and Limits Binding of the Viral pVII Protein to Virus DNA.

Authors:  Kwangchol Mun; Tanel Punga
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  A Combined In Vivo HSC Transduction/Selection Approach Results in Efficient and Stable Gene Expression in Peripheral Blood Cells in Mice.

Authors:  Hongjie Wang; Maximilian Richter; Nikoletta Psatha; Chang Li; Jiho Kim; Jing Liu; Anja Ehrhardt; Susan K Nilsson; Benjamin Cao; Donna Palmer; Philip Ng; Zsuzsanna Izsvák; Kevin G Haworth; Hans-Peter Kiem; Thalia Papayannopoulou; André Lieber
Journal:  Mol Ther Methods Clin Dev       Date:  2017-11-10       Impact factor: 6.698

3.  One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors.

Authors:  Maren Schiwon; Eric Ehrke-Schulz; Andreas Oswald; Thorsten Bergmann; Thomas Michler; Ulrike Protzer; Anja Ehrhardt
Journal:  Mol Ther Nucleic Acids       Date:  2018-06-07       Impact factor: 8.886

4.  iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy.

Authors:  Dominik Brücher; Nicole Kirchhammer; Sheena N Smith; Jatina Schumacher; Nina Schumacher; Jonas Kolibius; Patrick C Freitag; Markus Schmid; Fabian Weiss; Corina Keller; Melanie Grove; Urs F Greber; Alfred Zippelius; Andreas Plückthun
Journal:  Mol Ther Methods Clin Dev       Date:  2021-01-20       Impact factor: 6.698

5.  CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.

Authors:  Eric Ehrke-Schulz; Maren Schiwon; Theo Leitner; Stephan Dávid; Thorsten Bergmann; Jing Liu; Anja Ehrhardt
Journal:  Sci Rep       Date:  2017-12-07       Impact factor: 4.379

6.  Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma.

Authors:  Masakazu Yoshida; Etsuko Yokota; Tetsushi Sakuma; Tomoki Yamatsuji; Nagio Takigawa; Toshikazu Ushijima; Takashi Yamamoto; Takuya Fukazawa; Yoshio Naomoto
Journal:  Oncotarget       Date:  2018-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.